20 Sep 2022

CBD Active Pharmaceutical Ingredients (brochure)

PDF 5.7 MB

Make a difference with cannabinoid-based pharmaceuticals: the new frontier of medical science. The cannabinoid-based drug market is growing rapidly, powered by increasing scientific research indicating the positive therapeutic potential of cannabinoid actives, mostly CBD, in a wide variety of health areas, including CNS (central nervous system) diseases, pain disorders, cancer, and more. Download our brochure to learn more! 

Content provided by our supplier


  • CH
  • 2015
    On CPHI since
  • 1
  • 5000+
Company types
Primary activities
API Producer

Other Content from DSM (5)

  • News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical

    At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedical.  
  • Brochure DSM Pharma Partner Brochure 2022

    DSM is a global, purpose-led, science-based company active in health, nutrition, and bioscience. We help build, agile, and safe therapeutic innovations that help keep the world’s growing population healthy and improve the quality of patients’ lives. Our purpose is to create brighter lives for people today and for generations to come. As a global leader in vitamin and lipid manufacturing, DSM leverages its active pharmaceutical ingredient (API) offerings as proven, safe, and innovative agents for life-changing therapies. We draw on our unique skills in chemical synthesis and biotechnology to ensure all products meet strict sustainability standards. Download our partner brochure and discover our offering! 
  • Technical Data Nitrosamines risk-mitigation (factsheet)

    We understand that meeting new regulatory requirements concerning nitrosamine formation in drug products can come with unique and complex challenges. As your purpose-led innovation partner in the pharmaceutical industry, we can offer potential solutions to address this pressing issue. 
  • Whitepaper Combining drug therapies with Medical Nutrition solutions (whitepaper)

    Malnutrition is common in many patients and can lead to several complications that negatively impact prognosis and clinical outcomes. Getting the right nutritional care in a timely manner is therefore critical in championing the health of patients and promoting recovery and quality of life.This whitepaper explores the science-based benefits of combining disease-modifying oncology therapies with targeted medical nutrition products. It will then cover how DSM can support pharmaceutical manufacturers in evolving their portfolio from drug treatments only, to offer more integrated therapeutic solutions. The paper does not imply the use of medical nutrition as a substitute for drug therapy. 
  • Video Where others see products, we see purpose (video)

    At DSM, we deliver passion, innovation, and scientific expertise for every stage of your product's life cycle. This takes more than active pharmaceutical ingredients. It takes a partner.